New guidelines emphasize combination bronchodilators as a mainstay of therapy for many
patients with symptomatic COPD and there are several new combination bronchodilator …

Background Several new fixed-dose combination bronchodilators have been recently
launched, and assessing their efficacy relative to each other, and with open dual …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality,
and its prevalence is rising worldwide. Bronchodilators remain the cornerstone of COPD …

The Global Obstructive Lung Disease (GOLD) guidelines suggest the potential use of
combination bronchodilator therapy in patients with stage II or higher chronic obstructive …

Rationale: There is uncertainty on the use of using triple therapy (inhaled
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …

The incidence of chronic obstructive pulmonary disease (COPD) is rising in the United
States, and the disease represents a significant source of morbidity and mortality. Primary …

Pharmacological medications used for the treatment of COPD patients have increased
significantly. Long-acting bronchodilators have been recognized as the mainstay of the …

Introduction: Patients with chronic obstructive pulmonary disease (COPD) increasingly
receive combination bronchodilator therapies. Real world evidence for the benefits of …

Chronic obstructive pulmonary disease (COPD) is a respiratory syndrome affecting more
than 80 million people worldwide and is estimated to become the third-leading cause of …

Guidelines are mainly based on evidence of well-designed randomized controlled trials
(RCTs), but there are limitations to the transferability of conclusions of RCTs to usual care …